{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:02:05Z","timestamp":1776272525895,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13300-025-01821-9","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:18:45Z","timestamp":1764314325000},"page":"217-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of Freestyle Libre Systems for People with Type\u00a02 Diabetes Mellitus on Basal Insulin Therapy in the Netherlands: An Economic Evaluation from a Societal Perspective Within a Publicly Funded Healthcare System"],"prefix":"10.1007","volume":"17","author":[{"given":"Peter","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2209-9754","authenticated-orcid":false,"given":"Chris","family":"Chesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Timmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk","family":"Szafranski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur","family":"Levrat-Guillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"1821_CR1","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2147\/DMSO.S445288","volume":"17","author":"JA Overbeek","year":"2024","unstructured":"Overbeek JA, Nijpels G, Swart KMA, Blom MT, Elders PJM, Herings RMC. Type\u00a02 diabetes, the epidemic: trends in prevalence and incidence, 2004\u20132020. Diabetes Metab Syndr Obes. 2024;17:1503\u20139.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1821_CR2","unstructured":"Vanhommerig J, Knottnerus B. Type\u00a01 and type\u00a02 diabetes mellitus in the Netherlands: prevalence and incidence in 2022 [Diabetes mellitus type\u00a01 en type\u00a02 in Nederland: prevalentie en incidentie in 2022]. 2024. https:\/\/www.nivel.nl\/nl\/publicatie\/diabetes-mellitus-type-1-en-type-2-nederland-prevalentie-en-incidentie-2022. Accessed 18 Jun 2025."},{"key":"1821_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049487","volume":"11","author":"RJ Geurten","year":"2021","unstructured":"Geurten RJ, Elissen AMJ, Bilo HJG, Struijs JN, van Tilburg C, Ruwaard D. Identifying and delineating the type\u00a02 diabetes population in the Netherlands using an all-payer claims database: characteristics, healthcare utilisation and expenditures. BMJ Open. 2021;11:e049487.","journal-title":"BMJ Open"},{"key":"1821_CR4","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1111\/dom.15105","volume":"25","author":"SAG de Vries","year":"2023","unstructured":"de Vries SAG, Bak JCG, Stangenberger VA, et al. Use of hospital care among Dutch diabetes patients. Diabetes Obes Metab. 2023;25:2268\u201378.","journal-title":"Diabetes Obes Metab"},{"key":"1821_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052592","volume":"12","author":"MRJ Mevissen","year":"2022","unstructured":"Mevissen MRJ, Geurten RJ, Hendriks SH, Elissen A, van Dijk PR, Bilo HJG. Distribution of care expenditures for men and women with type\u00a02 diabetes treated in primary care in the Netherlands: a case-control study (ZODIAC-59). BMJ Open. 2022;12:e052592.","journal-title":"BMJ Open"},{"key":"1821_CR6","first-page":"281","volume":"75","author":"ML Peters","year":"2017","unstructured":"Peters ML, Huisman EL, Schoonen M, Wolffenbuttel BHR. The current total economic burden of diabetes mellitus in the Netherlands. Neth J Med. 2017;75:281\u201397.","journal-title":"Neth J Med"},{"key":"1821_CR7","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025. Diabetes Care. 2024;48:S181\u2013S206.","DOI":"10.2337\/dc25-S009"},{"key":"1821_CR8","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type\u00a02 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753\u201386.","journal-title":"Diabetes Care"},{"key":"1821_CR9","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes\u20142025. Diabetes Care. 2024;48:S128\u2013S45.","DOI":"10.2337\/dc25-S006"},{"key":"1821_CR10","unstructured":"American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes\u20142025. Diabetes Care. 2024;48:S146\u2013S66."},{"issue":"Suppl 2","key":"1821_CR11","first-page":"S3","volume":"18","author":"D Rodbard","year":"2016","unstructured":"Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(Suppl 2):S3\u201313.","journal-title":"Diabetes Technol Ther"},{"key":"1821_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/dia.2022.0271","volume":"25","author":"B Guerci","year":"2023","unstructured":"Guerci B, Roussel R, Levrat-Guillen F, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre system initiation in people with type\u00a02 diabetes on basal insulin therapy in France. Diabetes Technol Ther. 2023;25:20\u201330.","journal-title":"Diabetes Technol Ther"},{"key":"1821_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00125-024-06289-z","volume":"68","author":"D Nathanson","year":"2025","unstructured":"Nathanson D, Eeg-Olofsson K, Spelman T, et al. Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbA(1c) and a reduced risk of hospitalisation for diabetes-related complications in adults with type\u00a02 diabetes on insulin therapies. Diabetologia. 2025;68:41\u201351.","journal-title":"Diabetologia"},{"key":"1821_CR14","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1111\/dom.16266","volume":"27","author":"A Ratzki-Leewing","year":"2025","unstructured":"Ratzki-Leewing A, Harris SB, Rabasa-Lhoret R, Poon Y. Frontier: freestyle libre system use in Ontario among people with diabetes in the IC\/ES database-evidence from real-world practice: patients on basal insulin, glucagon-like peptide 1 receptor agonist or oral therapies. Diabetes Obes Metab. 2025;27:2637\u201346.","journal-title":"Diabetes Obes Metab"},{"key":"1821_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000809","volume":"7","author":"M Fokkert","year":"2019","unstructured":"Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care. 2019;7:e000809.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1821_CR16","unstructured":"Zorginstituut Nederland. Flash Glucose Monitoring in individuals with type\u00a01 and type\u00a02 diabetes mellitus on an intensive insulin regimen [Flash Glucose Monitoring bij personen met diabetes mellitus type\u00a01 en type\u00a02 met een intensief insulineschema]. 2019. https:\/\/www.zorginstituutnederland.nl\/publicaties\/standpunten\/2019\/12\/10\/fgm. Accessed 30 Jul 2025."},{"key":"1821_CR17","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1111\/dom.15703","volume":"26","author":"S Del Prato","year":"2024","unstructured":"Del Prato S, Giorgino F, Szafranski K, Poon Y. Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type\u00a02 diabetes mellitus on basal insulin therapy-an Italian healthcare system perspective. Diabetes Obes Metab. 2024;26:3633\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"1821_CR18","first-page":"917","volume":"30","author":"J Frank","year":"2024","unstructured":"Frank J, Son D, Szafranski K, Poon Y. Continuous glucose monitoring for self-management of diabetes in people living with type\u00a02 diabetes mellitus on basal insulin therapy: a microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid. J Manag Care Spec Pharm. 2024;30:917\u201328.","journal-title":"J Manag Care Spec Pharm"},{"key":"1821_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.01.010","author":"K Szafranski","year":"2024","unstructured":"Szafranski K, De Pouvourville G, Greenberg D, et al. The DEDUCE model, a cost-utility tool using patient-level microsimulation to evaluate sensor-based glucose monitoring systems in type\u00a01 and type\u00a02 diabetes: comparative validation. Value Health. 2024. https:\/\/doi.org\/10.1016\/j.jval.2024.01.010.","journal-title":"Value Health"},{"key":"1821_CR20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S2213-8587(17)30221-8","volume":"5","author":"S Basu","year":"2017","unstructured":"Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of risk equations for complications of type\u00a02 diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5:788\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1821_CR21","doi-asserted-by":"crossref","unstructured":"The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type\u00a02 Diabetes. N Engl J Med. 2008;358:2545\u201359.","DOI":"10.1056\/NEJMoa0802743"},{"key":"1821_CR22","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare. 2024. https:\/\/english.zorginstituutnederland.nl\/documents\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare. Accessed 19 Jun 2025."},{"key":"1821_CR23","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/dom.14949","volume":"25","author":"R Aronson","year":"2023","unstructured":"Aronson R, Brown RE, Chu L, et al. Impact of flash glucose monitoring in people with type\u00a02 diabetes inadequately controlled with non-insulin antihyperglycaemic therapy (IMMEDIATE): a randomized controlled trial. Diabetes Obes Metab. 2023;25:1024\u201331.","journal-title":"Diabetes Obes Metab"},{"key":"1821_CR24","doi-asserted-by":"publisher","DOI":"10.2337\/db20-84-LB","author":"E Miller","year":"2020","unstructured":"Miller E, Brandner L, Wright E. 84-LB: HbA1c reduction after initiation of the FreeStyle Libre system in type\u00a02 diabetes patients on long-acting insulin or noninsulin therapy. Diabetes. 2020. https:\/\/doi.org\/10.2337\/db20-84-LB.","journal-title":"Diabetes"},{"key":"1821_CR25","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab013","volume":"5","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal RM, Kerr MSD, Roberts GJ, Souto D, Nabutovsky Y, Hirsch IB. Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type\u00a02 diabetes. J Endocr Soc. 2021;5:bvab013.","journal-title":"J Endocr Soc"},{"key":"1821_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126427","volume":"10","author":"CL Edridge","year":"2015","unstructured":"Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type\u00a02 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS ONE. 2015;10:e0126427.","journal-title":"PLoS ONE"},{"key":"1821_CR27","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/imj.14842","volume":"51","author":"I Sagy","year":"2021","unstructured":"Sagy I, Zimhony-Nissim N, Brandstaetter E, et al. Outcomes of diabetic ketoacidosis in a tertiary centre with restricted intensive care unit bed capacity. Intern Med J. 2021;51:948\u201354.","journal-title":"Intern Med J"},{"key":"1821_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019864","volume":"8","author":"S de Groot","year":"2018","unstructured":"de Groot S, Enters-Weijnen CF, Geelhoed-Duijvestijn PH, Kanters TA. A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. BMJ Open. 2018;8:e019864.","journal-title":"BMJ Open"},{"key":"1821_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221856","volume":"14","author":"AV van Schoonhoven","year":"2019","unstructured":"van Schoonhoven AV, Gout-Zwart JJ, de Vries MJS, et al. Costs of clinical events in type\u00a02 diabetes mellitus patients in the Netherlands: a systematic review. PLoS ONE. 2019;14:e0221856.","journal-title":"PLoS ONE"},{"key":"1821_CR30","unstructured":"Netherlands Central Bureau of Statistics. Personal income [Inkomen van personen]. 2024. https:\/\/longreads.cbs.nl\/materiele-welvaart-in-nederland-2024\/inkomen-van-personen\/. Accessed 18 Jun 2025."},{"key":"1821_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00592-018-1244-6","volume":"56","author":"M Takahara","year":"2019","unstructured":"Takahara M, Katakami N, Shiraiwa T, et al. Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L. Acta Diabetol. 2019;56:309\u201319.","journal-title":"Acta Diabetol"},{"key":"1821_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jval.2016.10.007","volume":"20","author":"LS Matza","year":"2017","unstructured":"Matza LS, Stewart KD, Davies EW, Hellmund R, Polonsky WH, Kerr D. Health state utilities associated with glucose monitoring devices. Value Health. 2017;20:507\u201311.","journal-title":"Value Health"},{"key":"1821_CR33","first-page":"73","volume":"14","author":"SP Bilir","year":"2018","unstructured":"Bilir SP, Hellmund R, Wehler B, Li H, Munakata J, Lamotte M. Cost-effectiveness analysis of a flash glucose monitoring system for patients with type\u00a01 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14:73\u20139.","journal-title":"Eur Endocrinol"},{"key":"1821_CR34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/0272989X16658660","volume":"36","author":"T Peasgood","year":"2016","unstructured":"Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type\u00a0I diabetes. Med Decis Making. 2016;36:1020\u201333.","journal-title":"Med Decis Making"},{"key":"1821_CR35","unstructured":"CADTH. New drugs for type\u00a02 diabetes: second-line therapy - science report. 2017. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/TR0012_T2D_Science_Report.pdf. Accessed 26 Aug 2025."},{"key":"1821_CR36","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-019-00775-8","volume":"37","author":"H Shao","year":"2019","unstructured":"Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating quality of life decrements due to diabetes complications in the United States: the health utility index (HUI) diabetes complication equation. Pharmacoeconomics. 2019;37:921\u20139.","journal-title":"Pharmacoeconomics"},{"key":"1821_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.diabres.2018.01.007","volume":"138","author":"R Aronson","year":"2018","unstructured":"Aronson R, Galstyan G, Goldfracht M, Al Sifri S, Elliott L, Khunti K. Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetes Res Clin Pract. 2018;138:35\u201343.","journal-title":"Diabetes Res Clin Pract"},{"key":"1821_CR38","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/17843286.2021.2015554","volume":"77","author":"W Jorissen","year":"2022","unstructured":"Jorissen W, Annemans L, Louis N, Nilsson A, Willis M. Health economic modelling of diabetic kidney disease in patients with type\u00a02 diabetes treated with canagliflozin in Belgium. Acta Clin Belg. 2022;77:945\u201354.","journal-title":"Acta Clin Belg"},{"key":"1821_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002590","volume":"10","author":"AL Carlson","year":"2022","unstructured":"Carlson AL, Daniel TD, DeSantis A, et al. Flash glucose monitoring in type\u00a02 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diabetes Res Care. 2022;10:e002590.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1821_CR40","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jval.2025.03.002","volume":"28","author":"HA Geuzinge","year":"2025","unstructured":"Geuzinge HA, El Alili M, Enzing JJ, Huis in \u2019t Veld LM, Knies S, de Wit GA. The new Dutch guideline for economic evaluations in healthcare: taking the societal perspective to the next level. Value Health. 2025;28:930\u20135.","journal-title":"Value Health"},{"key":"1821_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13300-024-01677-5","volume":"16","author":"S Harris","year":"2025","unstructured":"Harris S, Cimino S, Nguyen Y, Szafranski K, Poon Y. Cost-effectiveness of FreeStyle Libre for glucose self-management among people with diabetes mellitus: a Canadian private payer perspective. Diabetes Ther. 2025;16:169\u201386.","journal-title":"Diabetes Ther"},{"key":"1821_CR42","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1111\/dom.13399","volume":"20","author":"AC Jalving","year":"2018","unstructured":"Jalving AC, Gant CM, Binnenmars SH, et al. Glycaemic control in the diabetes and Lifestyle Cohort Twente: a cross-sectional assessment of lifestyle and pharmacological management on Hba1c target achievement. Diabetes Obes Metab. 2018;20:2494\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1821_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110719","volume":"200","author":"MA Edens","year":"2023","unstructured":"Edens MA, van Dijk PR, Hak E, Bilo HJG. Determinants of excessive weight gain after the initiation of insulin therapy in type\u00a02 diabetes mellitus: retrospective inception cohort study (ZODIAC 60). Diabetes Res Clin Pract. 2023;200:110719.","journal-title":"Diabetes Res Clin Pract"},{"key":"1821_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015599","volume":"7","author":"AA van der Heijden","year":"2017","unstructured":"van der Heijden AA, Rauh SP, Dekker JM, et al. The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with type\u00a02 diabetes treated in primary care in the Netherlands. BMJ Open. 2017;7:e015599.","journal-title":"BMJ Open"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01821-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01821-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01821-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:43Z","timestamp":1771268623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01821-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01821-9","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peter van Dijk received study support from Abbott, Dexcom, and Menarini. All this support has gone to his employer. Kirk Szafranski is an employee of EVERSANA, which has received project funding from Abbott. Julia Bakker reports no relevant disclosures. Chris Chesters and Fleur Levrat-Guillen are employees of Abbott.\u00a0Jack Timmons was an employee of Abbott at the time this study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}